Organogenesis Holdings Inc (ORGO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Organogenesis Holdings Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 25.0% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.35 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.06 | – | 127 | 27.10 | 6.10 | 11 | 8 |
| 2025: Q1 | -0.15 | – | 87 | -21.20 | -21.70 | -20 | -24 |
| 2025: Q2 | -0.07 | – | 101 | -22.60 | -9.30 | -33 | -37 |
| 2025: Q3 | 0.16 | 79.00 | 151 | 30.70 | 14.30 | 3 | 1 |
| 2025: Q4 | 0.33 | 469.30 | 225 | 77.70 | 19.40 | 39 | 35 |
| 2026: Q1 | -0.44 | – | 37 | -57.10 | -150.90 | 21 | 18 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Organogenesis Holdings Inc. , a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
| Employees | 854 |
|---|---|
| Headquarters | Canton, MA |
| Website | organogenesis.com |
| IPO Date | 5. Jan 2017 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Gary S. Gillheeney Sr. | President, CEO, Chair of the Board | 1955 |
| David C. Francisco | Chief Financial Officer | 1966 |
| Patrick Bilbo | Chief Operating Officer | 1962 |
| Lori H. Freedman B.A., Esq., J.D. | Chief Administrative & Legal Officer | 1967 |
| Brian Grow | Chief Commercial Officer | 1976 |
| Patrick McGuire | Chief Accounting Officer | 1986 |
| Robert Cavorsi | Chief Business Officer | 1979 |
| William R. Kolb CPA | Secretary | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.